reports
Living Cell Technologies' NTCELL® Continues to Halt Progression of Pa...
SYDNEY & AUCKLAND, New Zealand--(BUSINESS WIRE)-- 130 weeks after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease remain well and there are no safety concerns. The primary clinical endpoint of this initial open clinical study, involving the implantation of 40 NTCELL capsules into the putamen on one side of the brain only, is safety. In all patients NTCELL treatment continues to show improvement over baseline, as measured by the Unifi...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Living Cell Technologies Group 1 Patients Successfully Treated in Park...
SYDNEY & AUCKLAND, New Zealand--(BUSINESS WIRE)-- Living Cell Technologies Limited has completed treatment of all six patients in group 1 of the Phase IIb clinical trial of NTCELL® for Parkinson’s disease, at Auckland City Hospital. Four patients had 40 NTCELL microcapsules implanted into the putamen on each side of their brain, and two patients had sham surgery with no NTCELL implanted. To date there are no safety issues in any of the six patients. The company is blind to the results until 26 weeks after completion of the tr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.